# Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas

> **NCT02598349** · PHASE2 · RECRUITING · sponsor: **Proton Collaborative Group** · enrollment: 60 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **RADIATION:** Proton Radiation
- **DRUG:** Capecitabine
- **PROCEDURE:** Surgical resection

## Key facts

- **NCT ID:** NCT02598349
- **Lead sponsor:** Proton Collaborative Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-04
- **Primary completion:** 2039-10
- **Final completion:** 2040-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02598349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02598349, "Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02598349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*